Pharmaceuticals, Biotechnology and Life Sciences
Camurus will start with the Phase 3 study of once-monthly octreotide subcutaneous depot for treatment of acromegaly CAM2029.
Swedish biotech company focused on autoimmune diseases, Cyxone is testing its drug candidate T20K, its first-in-human, phase I, clinical trial, for the treatment of multiple sclerosis (MS).
AstraZeneca’s Bevespi Aerosphere has been approved by the Japanese Ministry of Health, Labour and Welfare for patients with chronic obstructive pulmonary disease, becoming the first approved fixed-dose, long-acting dual bronchodilator in a pressurised metered-dose inhaler device in Japan.
Euromed, a Spain-based producer of standardized herbal extracts and natural active substances for pharmaceutical, nutraceutical and cosmetic industries, said Wednesday that, according to a recently published randomised, double-blind, placebo-controlled study, supplementation with Euromed’s natural extracts Pomanox™ and Mediteanox™ could help to maintain a healthy blood pressure, endothelial function and levels of circulating oxidised low-density lipoprotein cholesterol (oxLDL).
AstraZeneca and Merck revealed Wednesday that Lynparza (olaparib) has been approved in Japan as a maintenance treatment after 1st-line chemotherapy in patients with BRCA-mutated (BRCAm) advanced ovarian cancer, the only PARP inhibitor approved in Japan .
Boys and Girls Clubs of Canada (BGCC) has partnered with NARCAN Nasal Spray manufacturers, Adapt Pharma Canada, in the continued fight against the devastating fallout of Canada’s opioid crisis.
One of CARsgen Therapeutics’ leading drug candidates, CT053 fully human BCMA (B-Cell Maturation Antigen)-CAR-T cell for the treatment of patients suffering from relapsed/refractory multiple myeloma (rrMM), has received Investigational New Drug (IND) clearance from the United States Food and Drug Administration (FDA).
Japanese Ministry of Health, Labour, and Welfare has granted a second manufacturing and marketing approval for Myriad Genetics’ subsidiary, Myriad Genetic Laboratories, for BRACAnalysis Diagnostic System as a companion diagnostic with the PARP inhibitor, Lynparza, marketed by AstraZeneca and Merck.
ObsEva’s has recently cleared with the U.S. Food and Drug Administration (FDA) several important development issues for its oral oxytocin receptor antagonist nolasiban, which enables it to begin its U.S. Phase 3 clinical trial (IMPLANT 3) in the fourth quarter of this year or early 2020.
Arena Pharmaceuticals has dosed first patients in a trial called ELEVATE UC 52, which is the first of two pivotal trials within the Phase 3 registrational program designated to test etrasimod 2 mg in subjects with moderately to severely active ulcerative colitis (UC).